Ginkgo shares rose 13.4% after earnings, with investors likely responding to sharply lower losses and the company’s first autonomous-lab sale to a pharma company. The positive reaction comes despite declining revenue: Q3 revenue fell 6% year over year, and nine-month revenue was down 37%.
Shares plunged 9.3% following a steep 48% revenue decline and continued margin pressure, signaling investor disappointment with significant top-line deceleration and ongoing elevated losses despite cost-cutting efforts.
Ginkgo Bioworks reported a significant reduction in cash burn and reaffirmed its 2025 revenue guidance, despite a challenging environment in the biotechnology sector.
Ginkgo Bioworks reported a significant reduction in cash burn and costs, achieving a $250 million annual run rate savings three months ahead of schedule while guiding for continued revenue growth in 2025.